Sclerosing lichen (lichen sclerosus) is a chronic inflammatory skin disease characterized by disruption of the structure and function of the skin, the formation of seals and loss of tissue elasticity. The disease usually manifests itself on the genitals, perineum and anal area, but can also affect other areas of the skin. The causes of its occurrence are not fully understood, but they are assumed to be associated with autoimmune processes, as well as possible viral and infectious etiology. Sclerosing lichen can lead to significant life-threatening discomfort and even an increased risk of cancer.
History of the disease and interesting historical facts
Lichen sclerosus was first described in 1887 by Dr. Stokes, who described its clinical manifestations and treatment methods. Interestingly, at the beginning of the 20th century, it was believed that this disease was associated with an infection, but it was later proven to be of an autoimmune nature. Some historical documents related to the Bible may also mention diseases that are similar in symptoms to lichen sclerosus. Medical research shows that the belief in the existence of "unclean" diseases has been relevant for centuries.
Epidemiology
The epidemiology of lichen sclerosus remains the subject of active research, but there is already data on its prevalence. According to statistics, the incidence of this disease ranges from 0.1% to 0.6% among the population, and it is most often observed in women aged 40 to 60 years. In men, the disease is less common, and with age, the likelihood of developing lichen sclerosus increases significantly. The peak incidence is observed during menopause, which may indicate the role of hormonal changes in the pathogenesis of this disease.
Genetic predisposition to this disease
To date, genetic predisposition to lichen sclerosus has not been well studied, but some evidence suggests that genes involved may play a role. Studies suggest that mutations in genes associated with the immune response are seen among patients with the disease, in particular, this may be due to polymorphisms in the HLA genes. Genes such as HLA-DRB1 may influence the development of the disease, and the suggestion that lichen sclerosus has a genetic predisposition is supported by twin studies.
Risk factors for the development of this disease
There are several known risk factors that contribute to the development of lichen sclerosus. These include:
- Autoimmune diseases (eg, systemic lupus erythematosus, thyroiditis)
- Hormonal changes (eg menopause)
- Chemical factors (e.g. contact with irritants or carcinogens)
- Viral infections (possibly herpes viruses)
- Mood and stress (psychoemotional state can aggravate the course of diseases)
Diagnosis of this disease
Diagnosis of lichen sclerosus is based on clinical manifestations, which include pruritus, hypopigmentation, plaque formation, and skin atrophy. Laboratory tests may include autoantibody testing and skin biopsy for histologic examination to rule out other dermatologic diseases. Radiologic examinations, such as ultrasound or MRI, may also be used to evaluate the skin and detect complications. Differential diagnosis should include conditions such as psoriasis, eczema, and other dermatoses.
Treatment
Treatment of lichen sclerosus can be either conservative or surgical. The main focus is on reducing symptoms and improving the patient's quality of life. Conservative treatment may include:
- Hormonal therapy (corticosteroids can be used locally or systemically)
- Immunosuppressant drugs (eg, methotrexate)
- Physiotherapy procedures (eg laser therapy)
- General supportive care, including analgesia and anti-inflammatory drugs
Surgical treatment may be considered in cases of severe deformities or oncological changes caused by lichen sclerosus.
List of drugs used to treat this disease
The main groups of drugs used to treat lichen sclerosus include:
- Corticosteroids (eg, prednisolone, betamethasone)
- Immunosuppressants (eg, azathioprine, cyclosporine)
- Anti-inflammatory drugs (eg, ibuprofen)
- Interferons and drugs against herpes infection
Disease monitoring
Monitoring the condition of patients with lichen sclerosus requires periodic control over the course of the disease, assessment of symptoms and analysis of possible complications. It is important to conduct regular examinations to promptly identify possible changes in the skin condition and introduce the necessary corrections to the therapy. The prognosis of the disease in most cases is favorable, provided that adequate treatment is provided, however, there is a risk of developing malignant tumors against the background of a long-term inflammatory process.
Age-related features of the disease
Lichen sclerosus can manifest itself differently depending on the age of the patient. Children and the elderly tend to have more severe forms of the disease, while middle-aged people may have less severe symptoms. In postmenopausal women, the disease tends to be more severe, while in men, lichen sclerosus is less common, but has striking manifestations that require careful observation.
Questions and Answers
- What are the main symptoms of lichen sclerosus? The main symptoms are itching, redness, plaque formation, skin atrophy and discoloration.
- Is it possible to cure lichen sclerosus completely? There is currently no complete cure, but proper therapy can significantly improve the condition and reduce symptoms.
- What treatment is most effective for this disease? Local application of corticosteroids and immunosuppressive drugs, as well as physiotherapeutic methods, are effective.
- Is it necessary to follow a diet for lichen sclerosus? There are no specific dietary recommendations, but it is important to avoid contact with irritants.
- Is there a link between lichen sclerosus and cancer? Yes, long-term presence of lichen sclerosus may lead to an increased risk of developing malignant skin tumors.
